Overall survival (OS) results from the Phase II MagnetisMM-3 study of Pfizer’s (NYSE: PFE) Elrexfio (elranatamab-bcmm) in patients with heavily pre-treated relapsed or refractory multiple myeloma (RRMM), demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.
These data are being presented at Hematology Association (EHA) Hybrid Congress in Madrid, Spain.
The US Food and Drug Administration (FDA) granted accelerated approval to Elrexfio in August last year, and this was followed by conditional approval from the European Commission (EC) in December.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze